Results From 10-Patient Case Study Lead to Phase III Clinical Trial for Patients with Duchenne Muscular Dystrophy
Cedars-Sinai Heart Institute researchers have found that a commonly prescribed drug restores blood flow to oxygen-starved muscles of boys with
Duchenne muscular dystrophy, a genetic muscle-wasting disease that rarely is seen in girls but affects one in 3,500 male babies, profoundly shortening life expectancy. It is the most common fatal disease that affects children.
Muscle weakness begins in early childhood, often causing deformity of the arms, legs and spine. Heart and respiratory muscles often begin to fail before children reach early teen years. Although steroid medications – which often are not well tolerated – and other therapies may ease symptoms and delay the most severe effects, no disease-specific treatment exists, and patients rarely survive into their 30s.
But in this case study of 10 boys with Duchenne muscular dystrophy, also called DMD, a single dose of a drug often prescribed for erectile dysfunction or pulmonary hypertension corrected defective blood vessel mechanisms and restored blood flow to exercising muscles.
“The effects were immediate and dramatic, raising the question: If a single dose restores blood flow to muscle while the drug is in the patient’s system, could ongoing tadalafil administration provide sustained benefits, possibly preserve muscle and slow disease progression? If so, this would offer a new therapeutic strategy for DMD, and we have launched a randomized Phase III clinical trial to find out,” said Ronald Victor, MD, director of the Cedars-Sinai Center for Hypertension, associate director of clinical research at the Heart Institute and the Burns and Allen Chair in Cardiology Research. He is the senior author of a highlighted article in the May 7 online edition of Neurology.
Duchenne muscular dystrophy results from a genetic defect that eliminates a protein called dystrophin in the membranes of muscle cells. For more than 25 years, Victor has studied DMD and a less aggressive but debilitating variant called Becker muscular dystrophy. This form of muscular dystrophy, usually diagnosed in early adulthood, is caused by a reduction, but not absence, of dystrophin.
Victor led a research team that in 2000 discovered that the blood flow abnormality in the muscles of children with DMD was caused by a loss of nitric oxide, a signaling chemical that normally tells blood vessels to relax during exercise, increasing blood flow and oxygenation.
In studies of mice bred to represent diseases of dystrophin deficiency, the researchers found that drugs prescribed for other disorders of blood vessel function could restore muscle blood flow and enable the animals to exercise more, with less muscle injury. Tadalafil, known by the brand names Cialis and Adcirca, and sildenafil, called Viagra and Revatio, have long been approved by the Food and Drug Administration to treat erectile dysfunction and pulmonary hypertension, a serious illness that restricts blood flow to the lungs.
Translating these findings to a human clinical trial, Victor and his colleagues published in 2012 a study showing that tadalafil fully restored blood flow in eight of nine patients with Becker muscular dystrophy.
In the new study, investigators found that when boys with Duchenne muscular dystrophy performed handgrip exercises, the major artery of the arm and the blood vessels in muscles of the forearm failed to respond the way they did in healthy boys of similar ages, 8 to 13. But when the boys with DMD were given a single dose of tadalafil, normal vessel function and blood flow were restored. Similar results occurred when sildenafil, a drug with a similar mechanism of action on vessels but a different chemical structure, was used in place of tadalafil.
“Steroids and cardiac-protective blood pressure medication are increasingly prescribed at early ages for patients with Duchenne muscular dystrophy in an effort to delay by a few years the most devastating effects of the disease. But these treatments have no effect on the blood vessel dysfunction that prevents muscles from getting the oxygen they need,” said Victor. “In contrast, in our study, a single dose of tadalafil or sildenafil had an immediate effect. These are well-studied, well-tolerated drugs that are already on the market. If additional study confirms their benefits, repurposing the drugs for muscular dystrophy patients could quickly transform clinical practice.”
The Latest on: Duchenne muscular dystrophy
via Google News
The Latest on: Duchenne muscular dystrophy
- Duchenne Muscular Dystrophy: Rep. Frey, Gov. Lamont raise awareness for rare diseaseon November 19, 2019 at 1:51 pm
In this season of thanks, Ridgefield residents Christopher and Jessica Curran expressed gratitude to both State Representative John Frey (R-111) and Governor Ned Lamont for working together in a ...
- JAR 914: Father Declares War on Duchenne Muscular Dystrophyon November 19, 2019 at 12:56 pm
Outline: New Jersey dad declares war on son's incurable disease - Duchenne Muscular Dystrophy. JAR of Hope nonprofit funds start of medical infusions to slow rare disease that effects 20,000 in U.S..
- Press Release: Santhera Announces Publication of Long-term Idebenone Data from SYROS Study in Duchenne Muscular Dystrophyon November 18, 2019 at 10:03 pm
reduced from -5.9% 'Off-Idebenone' to -1.9% 'On-Idebenone'. -- The annual rate of decline in FVC%p and PEF%p remained stable year after year for the entire follow-up time of up to six years and was ...
- Santhera Announces Publication of Long-term Idebenone Data from SYROS Study in Duchenne Muscular Dystrophyon November 18, 2019 at 9:00 pm
Buyse, MD, PhD, Professor of Pediatrics and Child Neurology, University Hospitals Leuven (Leuven, Belgium). About Duchenne Muscular Dystrophy DMD is one of the most common and devastating types of ...
- A distant dream for us with muscular dystrophyon November 17, 2019 at 11:56 pm
Early symptoms include a wadding gait, pain and stiffness in muscles, difficulty sitting up or standing, walking on toes, frequent falls etc. Most common and severe form of muscular dystrophy is ...
- Becker muscular dystrophy caused by exon 2-truncating mutation of DMDon November 17, 2019 at 7:28 pm
Nonsense and frameshift mutations of the dystrophin (DMD) gene usually cause severe Duchenne muscular dystrophy (DMD). Interestingly, however, premature stop codons in exons 1 and 2 result in ...
- Duchenne Muscular Dystrophy Therapeutics Market Strategic Assessment by Top Players | Sarepta Therapeutics, Inc, Santhera Pharmaceuticalson November 13, 2019 at 8:33 pm
Nov 14, 2019 (WiredRelease via COMTEX) -- Duchenne Muscular Dystrophy Therapeutics Market by Growth 2020 – Technological Strategies, Business Advancements and Top-Vendor Landscape 2029, anticipated to ...
- Parent Project Muscular Dystrophy Launches New Duchenne Registry Appon November 12, 2019 at 4:23 pm
Leading Duchenne Organization Enhances 12-Year-Old Registry with New App, Empowering Families to Become Citizen Scientists by Contributing Data from the Palm of their Hand HACKENSACK, N.J., Nov. 12, ...
- University Of Pennsylvania Testing New Gene Therapy Targeting Duchenne Muscular Dystrophyon November 12, 2019 at 3:35 pm
PHILADELPHIA (CBS) — A new gene therapy treatment is being tested at the University of Pennsylvania to treat a rare kind of muscular dystrophy. It’s progressive and strikes mainly boys. One ...
- Trial of Gene Therapy for Duchenne Muscular Dystrophy Put on Holdon November 12, 2019 at 11:35 am
A clinical trial of a gene therapy for Duchenne muscular dystrophy has been halted after a patient suffered serious side effects following treatment, Reuters reports today (November 12). After ...
via Bing News